NZ591633A - Combination gas vaccines and therapeutics - Google Patents

Combination gas vaccines and therapeutics

Info

Publication number
NZ591633A
NZ591633A NZ591633A NZ59163309A NZ591633A NZ 591633 A NZ591633 A NZ 591633A NZ 591633 A NZ591633 A NZ 591633A NZ 59163309 A NZ59163309 A NZ 59163309A NZ 591633 A NZ591633 A NZ 591633A
Authority
NZ
New Zealand
Prior art keywords
protein
gas
antigens
mutant
amino acid
Prior art date
Application number
NZ591633A
Other languages
English (en)
Inventor
Andrea Manetti
Sabrina Capo
Giuliano Bensi
Guido Grandi
Y Ros Imma Margarit
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ591633A publication Critical patent/NZ591633A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ591633A 2008-09-17 2009-09-17 Combination gas vaccines and therapeutics NZ591633A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9755108P 2008-09-17 2008-09-17
PCT/IB2009/006949 WO2010076618A1 (en) 2008-09-17 2009-09-17 Combination gas vaccines and therapeutics

Publications (1)

Publication Number Publication Date
NZ591633A true NZ591633A (en) 2012-10-26

Family

ID=41508998

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591633A NZ591633A (en) 2008-09-17 2009-09-17 Combination gas vaccines and therapeutics

Country Status (18)

Country Link
US (2) US20100136041A1 (enExample)
EP (1) EP2344523B1 (enExample)
JP (2) JP5680536B2 (enExample)
CN (1) CN102356090B (enExample)
AU (1) AU2009334428B2 (enExample)
BR (1) BRPI0919236A8 (enExample)
CA (1) CA2737453A1 (enExample)
DK (1) DK2344523T3 (enExample)
ES (1) ES2566740T3 (enExample)
HR (1) HRP20160306T1 (enExample)
HU (1) HUE027618T2 (enExample)
MX (1) MX2011002760A (enExample)
NZ (1) NZ591633A (enExample)
PL (1) PL2344523T3 (enExample)
SI (1) SI2344523T1 (enExample)
SM (1) SMT201600125B (enExample)
WO (1) WO2010076618A1 (enExample)
ZA (1) ZA201102005B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
SMT201700275T1 (it) 2009-10-30 2017-07-18 Glaxosmithkline Biologicals Sa Purificazione di saccaridi capsulari di staphylococcus aureus tipo 5 e tipo 8
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
GB201206366D0 (en) 2012-04-11 2012-05-23 Absynth Biologics Ltd Bacterial vaccine
RU2662970C2 (ru) * 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
AU2015246654B2 (en) 2014-04-15 2019-08-08 Griffith University Group A streptococcus vaccine
WO2015169773A2 (en) * 2014-05-07 2015-11-12 Glaxosmithkline Biologicals S.A. Mutants of spy0269
US10329601B2 (en) * 2015-12-28 2019-06-25 Ionian Technologies, Inc. Nicking and extension amplification reaction (NEAR) of Streptococcus species
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
JP7601913B2 (ja) * 2021-01-19 2024-12-17 デンカ株式会社 タンパク質、溶血性連鎖球菌ワクチン、ｄｎａ、ベクター、形質転換体、タンパク質を製造する方法、バキュロウイルス、アグロバクテリウム、ラテックス粒子、キット及び抗ストレプトリジンｏ抗体の測定方法
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827038D0 (en) * 1988-11-18 1988-12-21 Kehoe M Streptolysin o antigens & uses
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
EP1648500B1 (en) * 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
AU2005294275B2 (en) * 2004-10-08 2012-09-13 Glaxosmithkline Biologicals S.A. Immunogenic and therapeutic compositions for Streptococcus pyogenes
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
AU2008299376B2 (en) * 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
NZ586430A (en) * 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)

Also Published As

Publication number Publication date
PL2344523T3 (pl) 2016-09-30
US20150132337A1 (en) 2015-05-14
AU2009334428A1 (en) 2010-07-08
US20100136041A1 (en) 2010-06-03
JP5680536B2 (ja) 2015-03-04
BRPI0919236A8 (pt) 2023-01-31
CN102356090A (zh) 2012-02-15
BRPI0919236A2 (pt) 2015-12-15
EP2344523B1 (en) 2016-02-10
SMT201600125B (it) 2016-07-01
JP2015038156A (ja) 2015-02-26
SI2344523T1 (sl) 2016-06-30
CA2737453A1 (en) 2010-07-08
WO2010076618A1 (en) 2010-07-08
DK2344523T3 (da) 2016-04-18
ZA201102005B (en) 2016-09-28
HRP20160306T1 (hr) 2016-04-22
HUE027618T2 (en) 2016-11-28
MX2011002760A (es) 2011-06-16
JP2012502969A (ja) 2012-02-02
AU2009334428B2 (en) 2014-02-20
CN102356090B (zh) 2016-01-20
EP2344523A1 (en) 2011-07-20
ES2566740T3 (es) 2016-04-15

Similar Documents

Publication Publication Date Title
NZ591633A (en) Combination gas vaccines and therapeutics
HRP20160638T1 (hr) Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin
BRPI0721003B8 (pt) composições e uso
JOP20190017B1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
MY182429A (en) Compositions relating to a mutant clostridium difficile toxin and methods thereof
NZ600348A (en) Anti-c5a binding moieties with high blocking activity
RU2011111700A (ru) Клостридиальные нейротоксины с измененной персистентностью
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
DE69735715D1 (de) Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
WO2015048484A4 (en) Binding moieties for biofilm remediation
EA201270517A1 (ru) Микобактериальные вакцины
BR112014030797A2 (pt) epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
WO2008127179A8 (en) Fusion protein vaccine
Okahashi et al. Pili of oral Streptococcus sanguinis bind to fibronectin and contribute to cell adhesion
JP2012502969A5 (enExample)
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2010092176A3 (en) Nontypable haemophilus influenzae antigens
MX2010002773A (es) Antigenos mutantes de gas57 y anticuerpos de gas57.
Sakaguchi et al. Genomics of Clostridium botulinum group III strains
Zvirbliene et al. Production and characterization of monoclonal antibodies against vaginolysin: Mapping of a region critical for its cytolytic activity
NZ702285A (en) Staphylococcal coagulase antigens and methods of their use
CN102942624B (zh) 一种半乳糖凝集素-3结合蛋白及其制备和应用
DE602005018615D1 (de) Schen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie
NZ720423A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
RU2009113831A (ru) Ipad-белок шигеллы и его применение в качестве вакцины против шигеллезных инфекций

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 SEP 2016 BY CPA GLOBAL

Effective date: 20130801

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH

Effective date: 20140409

LAPS Patent lapsed